Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Leukemia

Free Subscription 22.04.2024 1 Acta Haematol 6 Ann Hematol 1 Biochem Biophys Res Commun 6 Blood 2 BMC Cancer 3 Bone Marrow Transplant 1 Cancer Lett 1 Int J Hematol 1 J Clin Oncol 1 J Virol 1 Leuk Lymphoma 4 Leuk Res 4 Leukemia 1 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Acta Haematol

1. JIN X, Jiang X, Li H, Shen K, et al
   Prognostic Implications of Circulating Plasma Cell Percentage in Multiple Myeloma and Primary Plasma Cell Leukemia Defined by New Criteria.
   Acta Haematol. 2024 Apr 16. doi: 10.1159/000538658.
   PubMed         Abstract available
   
   

   
   Ann Hematol

2. THAU S, Poulsen CB, Brieghel C, Larsen MK, et al
   COVID-19 severity in patients with chronic lymphocytic leukemia treated with venetoclax: a single-center observational cohort study.
   Ann Hematol. 2024 Apr 18. doi: 10.1007/s00277-024-05738.
   PubMed         Abstract available
   
   
3. JEBANESAN DZP, Illangeswaran RSS, Rajamani BM, Vidhyadharan RT, et al
   Inhibition of NRF2 signaling overcomes acquired resistance to arsenic trioxide in FLT3-mutated Acute Myeloid Leukemia.
   Ann Hematol. 2024 Apr 17. doi: 10.1007/s00277-024-05742.
   PubMed         Abstract available
   
   
4. LEOTTA S, Markovic U, Duminuco A, Mule A, et al
   Impact of minimal residual disease response and of status of disease on survival after blinatumomab in B-cell acute lymphoblastic leukemia: results from a real-life study.
   Ann Hematol. 2024 Apr 13. doi: 10.1007/s00277-024-05725.
   PubMed         Abstract available
   
   
5. FRANKE GN, Loewe G, Reiser M, Linde H, et al
   Spotlight on the real-world treatment of CML pts in Germany: a retrospective survey in private oncology practices.
   Ann Hematol. 2024;103:1569-1575.
   PubMed         Abstract available
   
   
6. NISCOLA P, Gianfelici V, Giovannini M, Piccioni D, et al
   Very long-term efficacy of venetoclax combined with hypomethylating agents in two AML elderly: is it the time for treatment discontinuation strategies?
   Ann Hematol. 2024;103:1787-1788.
   PubMed        
   
   
7. SHUMILOV E, Mazzeo P, Ghandili S, Kunstner A, et al
   Diagnostic management of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in close interaction with therapeutic considerations.
   Ann Hematol. 2024;103:1587-1599.
   PubMed         Abstract available
   
   

   
   Biochem Biophys Res Commun

8. SUZUKI S, Liu J, Sato Y, Miyake R, et al
   Fucosylation inhibitor 6-alkynylfucose enhances the ATRA-induced differentiation effect on acute promyelocytic leukemia cells.
   Biochem Biophys Res Commun. 2024;710:149541.
   PubMed         Abstract available
   
   

   
   Blood

9. WOYACH JA, Perez Burbano G, Ruppert AS, Miller C, et al
   Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL.
   Blood. 2024;143:1616-1627.
   PubMed         Abstract available
   
   
10. RENGA G, Nunzi E, Stincardini C, Pariano M, et al
    CPX-351 exploits the gut microbiota to promote mucosal barrier function, colonization resistance, and immune homeostasis.
    Blood. 2024;143:1628-1645.
    PubMed         Abstract available
    
    
11. LAMBLE AJ, Rau RE
    IFN-gamma and CD38 in AML: a T-cell engagement made in heaven?
    Blood. 2024;143:1556-1557.
    PubMed        
    
    
12. CUNEO A, Ghia P
    Ibrutinib in CLL: benefit for all?
    Blood. 2024;143:1558-1559.
    PubMed        
    
    
13. BUFFET R
    How lipid coating soothes the gut in AML therapy.
    Blood. 2024;143:1559-1561.
    PubMed        
    
    
14. LANGERBEINS P, Giza A, Robrecht S, Cramer P, et al
    Reassessing the Chronic Lymphocytic Leukemia International Prognostic Index in the era of targeted therapies.
    Blood. 2024 Apr 15:blood.2023022564. doi: 10.1182/blood.2023022564.
    PubMed         Abstract available
    
    

    
    BMC Cancer

15. YI X, Zhan H, Lyu J, Du J, et al
    A chest CT-based nomogram for predicting survival in acute myeloid leukemia.
    BMC Cancer. 2024;24:458.
    PubMed         Abstract available
    
    
16. WANG L, Zhao S, Wang Y, Liu J, et al
    UBE2C promotes the proliferation of acute myeloid leukemia cells through PI3K/AKT activation.
    BMC Cancer. 2024;24:497.
    PubMed         Abstract available
    
    

    
    Bone Marrow Transplant

17. SHEN Y, Liu M, Shen D, Chu M, et al
    Busulfan plus cyclophosphamide vs. total body irradiation plus cyclophosphamide for allogeneic hematopoietic stem cell transplantation in patients with acute T lymphoblastic leukemia: a large-scale propensity score matching-based study.
    Bone Marrow Transplant. 2024 Apr 13. doi: 10.1038/s41409-024-02280.
    PubMed        
    
    
18. DONADEL CD, De Santis GC, Goncalves TE, Pires BG, et al
    Safety and efficacy of a new academic CD19-directed CAR-T cell for refractory/relapsed non-Hodgkin lymphoma and acute lymphoblastic leukemia in Brazil.
    Bone Marrow Transplant. 2024 Apr 13. doi: 10.1038/s41409-024-02283.
    PubMed        
    
    
19. NAGLER A, Labopin M, Swoboda R, Schroeder T, et al
    Post-transplant cyclophosphamide, calcineurin inhibitor, and mycophenolate mofetil compared to anti-thymocyte globulin, calcineurin inhibitor, and methotrexate combinations as graft-versus-host disease prophylaxis post allogeneic stem cell transplanta
    Bone Marrow Transplant. 2024 Apr 13. doi: 10.1038/s41409-024-02284.
    PubMed         Abstract available
    
    

    
    Cancer Lett

20. SUN H, Xie Y, Wu X, Hu W, et al
    circRNAs as prognostic markers in pediatric acute myeloid leukemia.
    Cancer Lett. 2024;591:216880.
    PubMed         Abstract available
    
    

    
    Int J Hematol

21. FUJITA H
    JSH practical guidelines for hematological malignancies, 2023: leukemia-2-acute promyelocytic leukemia (APL).
    Int J Hematol. 2024 Apr 17. doi: 10.1007/s12185-024-03749.
    PubMed        
    
    

    
    J Clin Oncol

22. TOBIASSON M, Pandzic T, Illman J, Nilsson L, et al
    Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation.
    J Clin Oncol. 2024;42:1378-1390.
    PubMed         Abstract available
    
    

    
    J Virol

23. PRAMONO D, Takeuchi D, Katsuki M, AbuEed L, et al
    FeLIX is a restriction factor for mammalian retrovirus infection.
    J Virol. 2024;98:e0177123.
    PubMed         Abstract available
    
    

    
    Leuk Lymphoma

24. TINAJERO J, Ngo D, Zhang J, Tsai NC, et al
    High remission rates and transition to allogeneic transplant in older patients with newly diagnosed FLT-3 mutated acute myelogenous leukemia with midostaurin plus intensive chemotherapy.
    Leuk Lymphoma. 2024 Apr 18:1-4. doi: 10.1080/10428194.2024.2332506.
    PubMed        
    
    

    
    Leuk Res

25. HU X, Cao P, Wang F, Wang T, et al
    Alternative polyadenylation quantitative trait loci contribute to acute myeloid leukemia risk genes regulation.
    Leuk Res. 2024;141:107499.
    PubMed         Abstract available
    
    
26. ZAD Z, Bonecker S, Wang T, Zalcberg I, et al
    Prediction of deep molecular response in chronic myeloid leukemia using supervised machine learning models.
    Leuk Res. 2024;141:107502.
    PubMed        
    
    
27. BERTON G, Sedaki B, Collomb E, Benachour S, et al
    Poor prognosis of SRSF2 gene mutations in patients treated with VEN-AZA for newly diagnosed acute myeloid leukemia.
    Leuk Res. 2024;141:107500.
    PubMed         Abstract available
    
    
28. ASHOURI K, Ginosyan AA, Chu M, Hom B, et al
    Donor matters: Donor selection impact on hematopoietic stem cell transplantation outcomes in Hispanic patients with B-cell acute lymphocytic leukemia: Insights from a myeloablative HSCT study.
    Leuk Res. 2024;141:107501.
    PubMed         Abstract available
    
    

    
    Leukemia

29. IYODA S, Yoshida K, Shoji K, Ito N, et al
    KRAS G12 mutations as adverse prognostic factors in KMT2A-rearranged acute myeloid leukemia.
    Leukemia. 2024 Apr 18. doi: 10.1038/s41375-024-02244.
    PubMed        
    
    
30. NORONHA N, Durette C, Cahuzac M, E Silva B, et al
    Autophagy degrades immunogenic endogenous retroelements induced by 5-azacytidine in acute myeloid leukemia.
    Leukemia. 2024 Apr 16. doi: 10.1038/s41375-024-02250.
    PubMed         Abstract available
    
    
31. CURIK N, Laznicka A, Polivkova V, Krizkova J, et al
    Combination therapies with ponatinib and asciminib in a preclinical model of chronic myeloid leukemia blast crisis with compound mutations.
    Leukemia. 2024 Apr 13. doi: 10.1038/s41375-024-02248.
    PubMed        
    
    
32. MATSUI S, Ri C, Bolanos LC, Choi K, et al
    Metabolic reprogramming regulated by TRAF6 contributes to the leukemia progression.
    Leukemia. 2024 Apr 12. doi: 10.1038/s41375-024-02245.
    PubMed         Abstract available
    
    

    
    PLoS One

33. KNOPPERS T, Haley CE, Bouhouita-Guermech S, Hagan J, et al
    From code to care: Clinician and researcher perspectives on an optimal therapeutic web portal for acute myeloid leukemia.
    PLoS One. 2024;19:e0302156.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.